RAN-EZETIMIBE TABLET

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

EZETIMIBE

から入手可能:

RANBAXY PHARMACEUTICALS CANADA INC.

ATCコード:

C10AX09

INN（国際名）:

EZETIMIBE

投薬量:

10MG

医薬品形態:

TABLET

構図:

EZETIMIBE 10MG

投与経路:

ORAL

パッケージ内のユニット:

28/100/500

処方タイプ:

Prescription

治療領域:

CHOLESTEROL ABSORPTION INHIBITORS

製品概要:

Active ingredient group (AIG) number: 0149164001; AHFS:

認証ステータス:

APPROVED

承認日:

2014-09-15

製品の特徴

_ _
_Pr_
_RAN™-EZETIMIBE (Ezetimibe Tablets) Product Monograph _
_Page 1 of 30_
_ _
PRODUCT MONOGRAPH
PR
RAN
™
-EZETIMIBE
Ezetimibe Tablets
10 mg
Cholesterol Absorption Inhibitor
Ranbaxy Pharmaceuticals Canada Inc.,
2680 Matheson Blvd. E., Suite 200
Mississauga, Ontario
L4W 0A5
Date of Preparation:
January 16, 2014
SUBMISSION CONTROL NO: 158635
Trademark owned by Ranbaxy Laboratories Limited
_ _
_Pr_
_RAN_
_™_
_-EZETIMIBE (Ezetimibe Tablets) Product Monograph _
_Page 2 of 30_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................7
DRUG INTERACTIONS
..................................................................................................11
DOSAGE AND ADMINISTRATION
..............................................................................13
OVERDOSAGE
................................................................................................................14
ACTION AND CLINICAL PHARMACOLOGY
............................................................14
STORAGE AND STABILITY
..........................................................................................16
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................16
PART II: SCIENTIFIC INFORMATION
...............................................................................17
PHARMACEUTICAL INFORMATION
..........................................................................17
CLINICAL TRIALS